<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ceftaroline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ceftaroline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ceftaroline: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16088" href="/d/html/16088.html" rel="external">see "Ceftaroline: Drug information"</a> and <a class="drug drug_patient" data-topicid="16089" href="/d/html/16089.html" rel="external">see "Ceftaroline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F11390165"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Teflaro</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F12828026"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Fifth Generation)</span></li></ul></div>
<div class="block don drugH1Div" id="F53669419"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection:</b> GA ≥34 weeks and PNA ≥12 days: IV: 6 mg/kg/dose every 8 hours; treatment duration is variable (5 to 14 days); dependent on severity of infection and clinical response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment:</b> Neonates (GA ≥34 weeks, PNA ≥12 days): <b>Note:</b> Renal function estimated using the Schwartz equation.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤50 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling, data is insufficient; use with caution, dosage adjustment may be necessary.</p></div>
<div class="block dop drugH1Div" id="F46725970"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ac90e46-b4a3-442b-b621-4d03cc8d4085">Cystic fibrosis pulmonary exacerbation, MRSA</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis (CF) pulmonary exacerbation, MRSA</b>: Very limited data available: Children ≥6 years and Adolescents: IV: 15 mg/kg/dose every 8 hours; maximum dose: 600 mg/dose. Dosing based on a prospective pharmacokinetic study in CF patients ≥6 years (n=7; total treatment courses: 10; age: mean: 20.3 ± 8 years; 43% of patients were &lt;18 years old) receiving ceftaroline for MRSA-positive respiratory secretions; the dosing regimen resulted in achievement of MIC ≥1 mcg/mL for &gt;60% of the time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29103924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29103924'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Treatment duration is dependent on severity of infection and clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children &lt;2 years: IV: 8 mg/kg/dose every 8 hours for 5 to 14 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">≤33 kg: IV: 12 mg/kg/dose every 8 hours for 5 to 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;33 kg: IV: 400 mg every 8 hours <b>or</b> 600 mg every 12 hours for 5 to 14 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: 600 mg every 12 hours for 5 to 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24f33387-1a13-489f-8e63-b1a313bd7f9a">Skin and skin structure infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection:</b> Treatment duration is variable (5 to 14 days); dependent on severity of infection and clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;2 months: IV: 6 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children &lt;2 years: IV: 8 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">≤33 kg: IV: 12 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;33 kg: IV: 400 mg every 8 hours <b>or</b> 600 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV: 600 mg every 12 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084357"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents &lt;18 years: <b>Note:</b> Renal function estimated using the Schwartz equation.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤50 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling, data is insufficient; use with caution, dosage adjustment may be necessary</p>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥18 years: <b>Note:</b> Renal function estimated using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 to ≤50 mL/minute: 400 mg every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥15 to ≤30 mL/minute: 300 mg every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: 200 mg every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD patients receiving hemodialysis: Dialyzable: 200 mg every 12 hours; dose should be given after hemodialysis on dialysis days</p></div>
<div class="block dohp drugH1Div" id="F51259755"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, ceftaroline is primarily renally eliminated.</p></div>
<div class="block doa drugH1Div" id="F11426126"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16088" href="/d/html/16088.html" rel="external">see "Ceftaroline: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Reserve for patients with or at risk for methicillin-resistant <i>S. aureus </i>infection who cannot receive preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32068643','lexi-content-ref-File.1','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32068643','lexi-content-ref-File.1','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for methicillin-resistant S. aureus: </i>
<b>IV: </b>600 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30858203','lexi-content-ref-31938716','lexi-content-ref-27895012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30858203','lexi-content-ref-31938716','lexi-content-ref-27895012'])">Ref</a></span>). For persistent or refractory cases or isolates with reduced susceptibility, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30858203','lexi-content-ref-31938716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30858203','lexi-content-ref-31938716'])">Ref</a></span>). Treat uncomplicated <i>S. aureus</i> bacteremia for ≥14 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Community-acquired pneumonia (alternative agent):</b></i> Inpatients without risk factors for <i>Pseudomonas aeruginosa</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 600 mg every 12 hours as part of an appropriate combination regimen. Total duration (including oral step-down therapy) is a minimum of 7 days for methicillin-resistant <i>S. aureus</i> (MRSA) infection; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>). <b>Note:</b> Switch to a narrower beta-lactam if MRSA is not isolated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hospital-</i></b>
<b>
<i>acquired or ventilator-associated pneumonia (alternative agent) (off-label use):</i></b>
<i>As a component of empiric therapy or as pathogen-directed therapy for methicillin-resistant S. aureus:</i>
<b>IV:</b> 600 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25956849','lexi-content-ref-31279152','lexi-content-ref-24621164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25956849','lexi-content-ref-31279152','lexi-content-ref-24621164'])">Ref</a></span>). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (alternative agent): IV:</b> 600 mg every 12 hours. Total duration of therapy is ≥5 days (including oral step-down therapy); may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20695801','lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20695801','lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992088"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Ceftaroline Fosamil Dose Adjustments for Altered Kidney Function<sup>a</sup>: IV</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl<sup>b</sup></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 600 mg IV every 12 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 600 mg IV every 8 hours</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>Recommendations are based on manufacturer's labeling, Riccobene 2014, and Sunzel 2015 (every 12-hour regimens) or expert opinion derived from Dryden 2016 (every 8-hour regimens).</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>b </sup>Estimated using the Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>c </sup>Dialyzable (22% to 73% recovered in dialysate [manufacturer's labeling; Sunzel 2015]): When scheduled doses fall on a dialysis day, one of the twice-daily doses should be administered after dialysis (Sunzel 2015).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;30 to ≤50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥15 to ≤30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hemodialysis, intermittent (thrice weekly)<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Peritoneal dialysis</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 8 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 600 mg every 8 hours infused over 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour), unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 600 mg every 12 hours: 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33438291','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33438291','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 600 mg every 8 hours: 400 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 600 mg every 12 hours: 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 600 mg every 8 hours: 400 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-PIRRT days: Dose according to patient's residual CrCl (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989295"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, ceftaroline is primarily renally eliminated.</p></div>
<div class="block adr drugH1Div" id="F11426102"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Positive direct Coombs test (10% to 18%; no evidence of hemolysis)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (adults: &lt;2%), palpitations (adults: &lt;2%), phlebitis (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (infants, children, and adolescents: &lt;3%), skin rash (3% to 7%), urticaria (adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (adults: &lt;2%), hyperkalemia (adults: &lt;2%), hypokalemia (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (adults: &lt;2%), <i>Clostridioides difficile</i> colitis (adults: &lt;2%), constipation (adults: 2%), diarrhea (5% to 8%), nausea (3% to 4%), vomiting (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (adults: &lt;2%), eosinophilia (adults: &lt;2%), neutropenia (adults: &lt;2%; risk may be increased with high doses and prolonged use [&gt;14 days]) (Sullivan 2019; Varada 2015), thrombocytopenia (adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (adults: &lt;2%), increased serum alanine aminotransferase (infants, children, and adolescents: &lt;3%), increased serum aspartate aminotransferase (infants, children, and adolescents: &lt;3%), increased serum transaminases (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (adults: &lt;2%), hypersensitivity reaction (adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (adults: &lt;2%), headache (infants, children, and adolescents: &lt;3%), seizure (adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome (adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (risk may be increased with high doses and prolonged use [&gt;14 days]) (Sullivan 2019; Varada 2015), leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (Srinivasan 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonia (Desai 2013)</p></div>
<div class="block coi drugH1Div" id="F11426100"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known serious hypersensitivity to ceftaroline, other members of the cephalosporin class, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F11426101"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: Seroconversion from a negative to a positive direct Coombs’ test has been reported. Hemolytic anemia was not reported in clinical studies; however, if anemia develops during or after treatment, consider drug-induced hemolytic anemia. Diagnostic tests should include a direct Coombs’ test. If hemolytic anemia is suspected, discontinue the drug and institute supportive care as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity (anaphylactic) and skin reactions have occurred with ceftaroline. Use with caution in patients with a history of penicillin, cephalosporin, or carbapenem allergy. Maintain clinical supervision if given to penicillin or beta-lactam allergic patients; cross sensitivity among beta-lactam antibacterial agents has been reported. If a serious reaction occurs, discontinue the drug and institute supportive measures as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Neurological reactions have been reported, including encephalopathy and seizures. Risk may be increased in the presence of renal impairment; ensure dose adjusted for renal function, and discontinue therapy if patient develops neurotoxicity; effects are often reversible upon discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neutropenia: Neutropenia and agranulocytosis have been reported; risk may be increased with high doses and prolonged therapy (&gt;14 days), patients with kidney dysfunction, and patients on concurrent antibiotics associated with neutropenia. Monitor CBC at baseline and at least weekly; limit duration of therapy when possible (Sullivan 2019; Varada 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis (including fatalities); CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (CrCl ≤50 mL/minute); dosage adjustments recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p></div>
<div class="block foc drugH1Div" id="F11390166"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Teflaro: 400 mg (1 ea); 600 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F11426096"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322874"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Teflaro Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $280.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $280.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614469"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Dilute prior to administration. Administer by IV infusion; infusion time is determined by age.</p>
<p style="text-indent:-2em;margin-left:2em;">Neonates (GA ≥34 weeks and PNA ≥12 days) and Infants &lt;2 months: Infuse over 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥2 months, Children, and Adolescents: Infuse over 5 to 60 minutes. <b>Note: </b>Has been infused over 120 minutes in patients with complicated community-acquired pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27078119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27078119'])">Ref</a></span>); 120-minute infusion is also recommended in European product labeling for high-dose therapy of complicated skin and soft tissue infections confirmed or suspected to be caused by <i>Staphylococcus aureus</i> isolates with minimum inhibitory concentration ≥2 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pfizer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pfizer.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F11426128"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by slow IV infusion over 5 to 60 minutes. <b>Note:</b> Some studies utilizing 8-hour regimens administered each infusion over 120 minutes, which may be beneficial for organisms with minimum inhibitory concentrations ≥2 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25700566','lexi-content-ref-27585969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25700566','lexi-content-ref-27585969'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F11426110"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store unused vials at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Diluted solutions in D2.5W, <sup>1</sup>/<sub>2</sub>NS, D5W, LR, or NS (in infusion bags or Mini-Bag Plus) should be used within 6 hours when stored at room temperature or within 24 hours if refrigerated at 2°C to 8°C (36°F to 46°F).</p></div>
<div class="block usep drugH1Div" id="F53570899"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of <i>Staphylococcus aureus</i> (including methicillin-susceptible and -resistant isolates), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Klebsiella oxytoca</i> (FDA approved in all ages); treatment of community-acquired pneumonia (CAP) caused by <i>Streptococcus pneumoniae</i> (including cases with concurrent bacteremia), <i>S. aureus</i> (methicillin-susceptible isolates only), <i>Haemophilus influenzae</i>, <i>K. pneumoniae</i>, <i>K. oxytoca</i>, and <i>E. coli</i> (FDA approved in ages ≥2 months and adults); has also been used for the treatment of cystic fibrosis pulmonary exacerbation</p></div>
<div class="block cyt drugH1Div" id="F13298995"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F11429548"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F11426098"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53570901"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function periodically; CBC; number and type of stools/day for diarrhea; monitor for signs of anaphylaxis during first dose</p></div>
<div class="block pha drugH1Div" id="F11426114"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) 1 through 3. This action blocks the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls and inhibits cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested. Ceftaroline has a strong affinity for PBP2a, a modified PBP in MRSA, and PBP2x in <i>S. pneumoniae</i>, contributing to its spectrum of activity against these bacteria.</p></div>
<div class="block phk drugH1Div" id="F11426116"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>The pharmacokinetics of ceftaroline in pediatric patients from 2 months to &lt;18 years of age were similar to those in adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Median: 20.3 L (range: 18.3 to 21.6 L)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~20%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Ceftaroline fosamil (inactive prodrug) undergoes rapid conversion to bioactive ceftaroline in plasma by phosphatase enzyme; ceftaroline is hydrolyzed to form inactive ceftaroline M-1 metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.6 ± 0.38 hours (single dose); 2.66 ± 0.4 hours (multiple dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~88%); feces (~6%)</p></div>
<div class="block phksp drugH1Div" id="F51192721"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased 52% in moderate renal impairment (CrCl &gt;30 to 50 mL/minute) and 115% in severe renal impairment (CrCl 15 to 30 mL/minute) as compared to patients with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The AUC was ~33% higher in elderly patients, mainly because of changes in renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC):</p>
<p style="text-indent:-2em;margin-left:6em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:8em;">Gram-positive organisms (eg, <i>S. aureus, S. pneumoniae</i>): Goal: ≥ ~30% <i>f</i>T &gt; MIC (1-log kill) (Andes 2006; MacGowan 2013).</p>
<p style="text-indent:-2em;margin-left:8em;">Gram-negative organisms (eg, <i>E. coli</i>, <i>K. pneumoniae</i>): Goal: ≥41% <i>f</i>T &gt; MIC (1-log kill) (Andes 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Population specific:</p>
<p style="text-indent:-2em;margin-left:8em;">Critically ill patients in the ICU: Minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt;4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Expected drug exposure in normal renal function<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients: Steady state: C<sub>max</sub> (peak): IV (1-hour infusion):</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm neonates: 6 mg/kg/dose every 8 hours:</p>
<p style="text-indent:-2em;margin-left:10em;">GA 36 to &lt;40 weeks: 12.4 to 12.8 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:10em;">GA 32 to &lt;36 weeks: 11.9 to 12.1 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:10em;">GA 30 to &lt;32 weeks: 11.4 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates and infants &lt;2 months of age: 6 mg/kg/dose every 8 hours: 13.4 to 14.1 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and children 2 months to &lt;2 years of age: 8 mg/kg/dose every 8 hours: 18.8 to 19.6 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;12 years of age: 12 mg/kg/dose every 8 hours (maximum dose: 400 mg/dose): 27.1 to 27.6 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and adolescents 12 to &lt;18 years of age:</p>
<p style="text-indent:-2em;margin-left:10em;">12 mg/kg/dose every 8 hours (maximum dose: 400 mg/dose): 19.7 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:10em;">600 mg every 12 hours: 28.6 mg/L (Riccobene 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients with cystic fibrosis: C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:8em;">Single dose: IV: 10 mg/kg, maximum dose: 600 mg (1-hour infusion).</p>
<p style="text-indent:-2em;margin-left:10em;">Children 6 to &lt;12 years of age: 25.5 ± 4.5 mg/L (Le 2017).</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents 12 to &lt;18 years of age: 27.9 ± 4.2 mg/L (Le 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:8em;">Single dose: 600 mg (1-hour infusion): IV:</p>
<p style="text-indent:-2em;margin-left:10em;">BMI &lt;30 kg/m<sup>2</sup>: 22.3 ± 5.9 to 22.6 ± 2 mg/L (Justo 2015; Matzneller 2016).</p>
<p style="text-indent:-2em;margin-left:10em;">BMI 30 to 34.9 kg/m<sup>2</sup>: 19.2 ± 3.8 mg/L (Justo 2015).</p>
<p style="text-indent:-2em;margin-left:10em;">BMI 35 to 39.9 kg/m<sup>2</sup>: 17.5 ± 2.4 mg/L (Justo 2015).</p>
<p style="text-indent:-2em;margin-left:10em;">BMI ≥40 kg/m<sup>2</sup>: 14.3 ± 1.4 mg/L (Justo 2015).</p>
<p style="text-indent:-2em;margin-left:8em;">Multiple dose: 600 mg every 12 hours (1-hour infusion): IV: 22 ± 4 mg/L (Matzneller 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Gram-positive organisms (eg, enterococci, <i>S. pneumoniae</i>, <i>S. aureus</i>): ≤2 hours (Pankuch 2009).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059488"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Teflaro</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Omvelin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Zinforo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper.<i> Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients.<i> J Antimicrob Chemother.</i> 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16569855">
<a name="16569855"></a>Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. <i>Antimicrob Agents Chemother</i>. 2006;50(4):1376-1383. doi:10.1128/AAC.50.4.1376-1383.2006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/16569855/pubmed" id="16569855" target="_blank">16569855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28131729">
<a name="28131729"></a>Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. <i>Int J Infect Dis</i>. 2017;57:27-31. doi:10.1016/j.ijid.2017.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/28131729/pubmed" id="28131729" target="_blank">28131729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29103924">
<a name="29103924"></a>Barsky EE, Pereira LM, Sullivan KJ, et al. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. <i>J Cyst Fibros</i>. 2018;17(3):e25-e31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/29103924/pubmed" id="29103924" target="_blank">29103924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32068643">
<a name="32068643"></a>Bassetti M, Magnasco L, Del Puente F, Giacobbe DR. Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. <i>Curr Opin Infect Dis</i>. 2020;33(2):110-120. doi:10.1097/QCO.0000000000000631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/32068643/pubmed" id="32068643" target="_blank">32068643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21115457">
<a name="21115457"></a>Biek D, Critchley IA, Riccobene TA, et al. Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin With Expanded Anti-Gram-Positive Activity. <i>J Antimicrob Chemother.</i> 2010;65(suppl 4):iv9-iv16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/21115457/pubmed" id="21115457" target="_blank">21115457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27078119">
<a name="27078119"></a>Blumer JL, Ghonghadze T, Cannavino C, et al. A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia. <i>Pediatr Infect Dis J</i>. 2016;35(7):760-766. doi:10.1097/INF.0000000000001160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/27078119/pubmed" id="27078119" target="_blank">27078119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25700566">
<a name="25700566"></a>Canut A, Isla A, Rodríguez-Gascón A. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. <i>Int J Antimicrob Agents</i>. 2015;45(4):399-405. doi:10.1016/j.ijantimicag.2014.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/25700566/pubmed" id="25700566" target="_blank">25700566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20695801">
<a name="20695801"></a>Corey GR, Wilcox M, Talbot GH, et al. Integrated Analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. <i>Clin Infect Dis</i>. 2010;51(6):641-650.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/20695801/pubmed" id="20695801" target="_blank">20695801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23649990">
<a name="23649990"></a>Desai KR, Burdette SD, Polenakovik HM, Hagaman J, Pleiman CM. Ceftaroline-induced eosinophilic pneumonia. <i>Pharmacotherapy</i>. 2013;33(7):e166-e169. doi:10.1002/phar.1286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/23649990/pubmed" id="23649990" target="_blank">23649990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27585969">
<a name="27585969"></a>Dryden M, Zhang Y, Wilson D, Iaconis JP, Gonzalez J. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. <i>J Antimicrob Chemother</i>. 2016;71(12):3575-3584. doi:10.1093/jac/dkw333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/27585969/pubmed" id="27585969" target="_blank">27585969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21067350">
<a name="21067350"></a>File TM Jr, Low DE, Eckburg PB, et al. Integrated Analysis of FOCUS 1and FOCUS 2: Randomized, Double-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone in Patients With Community-Acquired Pneumonia. <i>Clin Infect Dis</i>. 2010;51(12):1395-1405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/21067350/pubmed" id="21067350" target="_blank">21067350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30858203">
<a name="30858203"></a>Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. <i>Antimicrob Agents Chemother.</i> 2019;63(5):e02483-18. doi:10.1128/AAC.02483-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/30858203/pubmed" id="30858203" target="_blank">30858203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25896707">
<a name="25896707"></a>Justo JA, Mayer SM, Pai MP, et al. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. <i>Antimicrob Agents Chemother.</i> 2015;59(7):3956-3965. doi:10.1128/AAC.00498-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/25896707/pubmed" id="25896707" target="_blank">25896707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33438291">
<a name="33438291"></a>Kalaria S, Williford S, Guo D, et al. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. <i>Pharmacotherapy</i>. 2021;41(2):205-211. doi:10.1002/phar.2502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/33438291/pubmed" id="33438291" target="_blank">33438291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25956849">
<a name="25956849"></a>Kaye KS, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. <i>Hosp Pract (1995)</i>. 2015;43(3):144-149. doi:10.1080/21548331.2015.1037228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/25956849/pubmed" id="25956849" target="_blank">25956849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910514">
<a name="28910514"></a>Le J, Bradley JS, Hingtgen S, et al. Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis.<i> Pediatr Pulmonol.</i> 2017;52(11):1424-1434. doi:10.1002/ppul.23827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/28910514/pubmed" id="28910514" target="_blank">28910514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459495">
<a name="23459495"></a>MacGowan AP, Noel AR, Tomaselli S, Bowker KE. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. <i>Antimicrob Agents Chemother.</i> 2013;57(6):2451-2456. doi:10.1128/AAC.01386-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/23459495/pubmed" id="23459495" target="_blank">23459495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27044549">
<a name="27044549"></a>Matzneller P, Lackner E, Lagler H, Wulkersdorfer B, Österreicher Z, Zeitlinger M. Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil.<i> Antimicrob Agents Chemother.</i> 2016;60(6):3617-3625. doi:10.1128/AAC.00097-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/27044549/pubmed" id="27044549" target="_blank">27044549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31938716">
<a name="31938716"></a>McCreary EK, Kullar R, Geriak M, et al. Multicenter cohort of patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. <i>Open Forum Infect Dis</i>. 2019;7(1):ofz538. doi:10.1093/ofid/ofz538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/31938716/pubmed" id="31938716" target="_blank">31938716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45. doi:10.1086/599376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31279152">
<a name="31279152"></a>Pani A, Colombo F, Agnelli F, et al. Off-label use of ceftaroline fosamil: a systematic review. <i>Int J Antimicrob Agents</i>. 2019;54(5):562-571. doi:10.1016/j.ijantimicag.2019.06.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/31279152/pubmed" id="31279152" target="_blank">31279152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19770288">
<a name="19770288"></a>Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against gram-positive organisms. <i>Antimicrob Agents Chemother.</i> 2009;53(10):4537-4539. doi:10.1128/AAC.00785-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/19770288/pubmed" id="19770288" target="_blank">19770288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24621164">
<a name="24621164"></a>Pasquale TR, Tan MJ, Trienski TL, File TM Jr. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. <i>J Chemother</i>. 2015;27(1):29-34. doi:10.1179/1973947813Y.0000000156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/24621164/pubmed" id="24621164" target="_blank">24621164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24431097">
<a name="24431097"></a>Riccobene T, Jakate A, Rank D. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. <i>J Clin Pharmacol</i>. 2014;54(7):742-752. doi:10.1002/jcph.265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/24431097/pubmed" id="24431097" target="_blank">24431097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27510635">
<a name="27510635"></a>Riccobene TA, Khariton T, Knebel W, et al. Population PK modeling and target attainment simulations to support dosing of ceftaroline fosamil in pediatric patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.<i> J Clin Pharmacol.</i> 2017;57(3):345-355. doi:10.1002/jcph.809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/27510635/pubmed" id="27510635" target="_blank">27510635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis.</i> 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34094755">
<a name="34094755"></a>Srinivasan A, Bennie B, Viroliya K, Kesavan R, Sarva ST. Ceftaroline-associated encephalopathy: a rare adverse effect. <i>Cureus</i>. 2021;13(5):e14795. doi:10.7759/cureus.14795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/34094755/pubmed" id="34094755" target="_blank">34094755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31123688">
<a name="31123688"></a>Sullivan EL, Turner RB, O'Neal HR Jr, Crum-Cianflone NF. Ceftaroline-associated neutropenia: case series and literature review of incidence, risk factors, and outcomes. <i>Open Forum Infect Dis.</i> 2019;6(5):ofz168. doi:10.1093/ofid/ofz168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/31123688/pubmed" id="31123688" target="_blank">31123688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545441">
<a name="26545441"></a>Sunzel M, Learoyd M, Li J, Li Y, Ngo N, Edeki T. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis. <i>Int J Antimicrob Agents</i>. 2015;46(6):682-688. doi:10.1016/j.ijantimicag.2015.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/26545441/pubmed" id="26545441" target="_blank">26545441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.1">
<a name="Allergan.1"></a>Teflaro (ceftaroline fosamil) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26037689">
<a name="26037689"></a>Varada NL, Sakoulas G, Lei LR, Chua J. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. <i>Pharmacotherapy</i>. 2015;35(6):608-612. doi:10.1002/phar.1596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/26037689/pubmed" id="26037689" target="_blank">26037689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25574117">
<a name="25574117"></a>Vazquez JA, Maggiore CR, Cole P, Smith A, Jandourek A, Friedland HD. Ceftaroline fosamil for the treatment of <i>Staphylococcus aureus</i> bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. <i>Infect Dis Clin Pract (Baltim Md)</i>. 2015;23(1):39-43. doi:10.1097/IPC.0000000000000191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/25574117/pubmed" id="25574117" target="_blank">25574117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147169">
<a name="25147169"></a>Yam FK, Kwan BK. A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline. <i>AM J Health-Syst Pharm</i>. 2014;71(17):1457-1461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/25147169/pubmed" id="25147169" target="_blank">25147169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27895012">
<a name="27895012"></a>Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. <i>Antimicrob Agents Chemother</i>. 2017;61(2):e02015-16. doi:10.1128/AAC.02015-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftaroline-pediatric-drug-information/abstract-text/27895012/pubmed" id="27895012" target="_blank">27895012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Zinforo (ceftaroline fosamil) [EMA summary of product characteristics]. Ringaskiddy, Ireland: Pfizer Ireland Pharmaceuticals; July 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 109476 Version 97.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
